Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

In a letter to the patient advocacy group World Duchenne Organization on Monday, Roche (OTCQX:RHHBF) ... Update: 9.28 AM EST: Adds comments from Sarepta. More on Roche, Sarepta, etc.

Sarepta Therapeutics demanded a prominent patient advocacy organization censor a video that contained pointed criticism of the company’s recently approved gene therapy for Duchenne muscular ...

Sarepta posted Q1 2025 revenue of $744.86 million, beating the $683.36 million estimate. Full-year revenue guidance cut to $2.3 billion–$2.6 billion from prior $2.9 billion–$3.1 billion range ...

After Sarepta trial failure, families and doctors brace for another debate on Duchenne therapy. By Jason Mast and Adam Feuerstein Nov. 1, 2023. Reprints. Kristoffer Tripplaar/Sipa via AP.

Sarepta Forward Looking Statement This press release contains "forward-looking statements." Any statements contained in this press release that are not statements of historical fact may be deemed ...

Sarepta Therapeutics Inc said the U.S. drug regulator could initially approve its gene therapy for a muscle wasting disorder for a smaller patient group after the agency deferred an accelerated ...